CEO Siesta

The celebrates siesta Group – global leader in bedroom, LEP -, and Gehirnaktivitats analysis for clinical trials and research – 2012 its tenth anniversary of Vienna, 03.08.212 – the 2012 siesta group is celebrating its tenth anniversary. An event on the occasion of the round birthday in Vienna took place on June 21, 2012. Highlights of the event were the opening words of Georg Dorffner, CEO of the siesta group and the keynote speeches by Vladimir Svetnik, Director biometrics research, Merck & company and Bernd Saletu, Professor of Psychiatry and sleep medicine, Rudolfinerhaus, Vienna. The Siesta group is a comprehensive service provider in the area of analysis of sleep, alertness and brain activity/pharmaco-EEG in the context of clinical trials and research. Their services include consulting, data analysis, data quality control and the rental of the necessary technical equipment for extracting data. How started the siesta group their career? How has the company become the, what it is today? Fifteen years ago Sixteen partners from seven countries in the SIESTA, EU research project co-ordinated by the Austrian Research Institute for artificial intelligence (OFAI), participated and created the largest normative database for healthy sleep.

For the first time, it was possible to objectively describe anomalies in the sleep of patients taking into account age and gender. Five years later some members of the SIESTA of research project founded the company the Group siesta. The goal was the results of the EU project continues to develop and to make them available in the field of sleep medicine and research for people all over the world. in 2004, the siesta group with the launch of the Somnolyzer 24 x 7 set a milestone in sleep medicine. This ground-breaking software converts raw sleep data objectively and reliably into standard sleep profiles and provides a solid base thus sleep specialists for diagnosis. For the first time, it was pharmaceutical companies to take advantage of possible computer-aided sleep analyses in clinical trials and the Reliability of evaluations and their low variability to benefit.

Comments are closed.